Planning for the HPV vaccine and its impact on cervical cancer prevention

Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–527. Cupp MR, Malek RS, Goellner JR, Smith TF, Espy MJ, The detection of human papillomavirus deoxyribonucleic acid in intraepithelial, in situ, verrucous and invasive carcinoma of the penis. J Urol 1995;154:1024–1029. Frisch M. On the etiology of anal squamous carcinoma. Dan Med Bull 2002;49:194–209. Stubenrauch F, Laimins LA. Human papillomavirus life cycle: active and latent phases. Semin. Cancer Biol 1999;9:379–386. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–428. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157:218–226. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004;4:46–54. Burk RD. Human papillomavirus and the risk of cervical cancer. Hosp Pract (Off Ed) 1999;34:103–111. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3–8. Rhea WG Jr, Bourgeois BM, Sewell DR. Condyloma acuminata: a fatal disease? Am Surg 1998;64:1082–1087. Bosch FX, Castellsague X, Munoz N, et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer Inst 1996;88:1060–1067. Lajous M, Mueller N, Cruz-Valdez A, et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev 2005;14:1710–1716. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis 2006;6:21–31. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995–3002. ACOG practice bulletin. Cervical cytology screening. Int J Gynaecol Obstet 2003;83:237–247. Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol 2001;185:308–317. White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 1998;72:959–964. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271–278. Mao C, Koutsky LA, Ault KA, et al. Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial. Obstet Gynecol 2006;107:18–27. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645–1651. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004;2:343–347. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003;348:489–490. Jastreboff AM, Cymet TC. Role of human papilloma virus in the development of cervical intraepithelial neoplasi and malignancy Postgrad Med J 2002;78:225–228